Rein Therapeutics (RNTX) Income towards Parent Company (2016 - 2026)

Rein Therapeutics (RNTX) has reported Income towards Parent Company for 11 consecutive years, with -$5.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 15.5% year-over-year to -$5.5 million; the TTM figure through Mar 2026 stood at -$51.3 million (up 48.99% YoY), while the FY2025 annual figure was -$50.7 million, up 38.16% from the prior year.
• Income towards Parent Company advanced to -$5.5 million in Q1 2026 per RNTX's latest filing, from -$32.8 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$2.0 million in Q3 2023 and bottomed at -$82.1 million in Q4 2022.
• Historically, Income towards Parent Company has averaged -$18.1 million across 5 years, with a median of -$8.2 million in 2022.
• Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 75.69% — and 2024, when it plunged 469.13%.
• Rein Therapeutics' Income towards Parent Company stood at -$82.1 million in 2022, then jumped by 68.58% to -$25.8 million in 2023, then sank by 183.93% to -$73.2 million in 2024, then surged by 55.22% to -$32.8 million in 2025, then jumped by 83.08% to -$5.5 million in 2026.
• Business Quant data shows RNTX's Income towards Parent Company at -$5.5 million in Q1 2026, -$32.8 million in Q4 2025, and -$5.6 million in Q3 2025.